Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
PMID 31993631
It has shown potential for supporting the management of chronic gastrointestinal conditions, such as inflammatory bowel diseases (IBD), including ulcerative colitis (UC)
At this time, we do not accept insurance
Mechanistic Understanding Gaps Fundamental aspects of combination pharmacology require clarification[23]: Receptor-level interactions between components unknown (synergistic, additive, or antagonistic) Optimal dosing sequences and escalation protocols not scientifically established Tissue-specific distribution of combined formulation requires investigation Metabolic pathway interactions between incretin and amylin systems incompletely mapped Whether combination provides true synergy or simply additive effects remains unclear Population-Specific Considerations Research gaps exist for specific populations[24]: Renal impairment effects on peptide clearance inadequately studied Hepatic dysfunction impact on safety profile unclear Elderly populations (over 75 years) underrepresented in trials Racial and ethnic diversity in study populations limited Patients with cardiovascular disease require additional safety data Regulatory & Competitive Sport Status FDA Position Neither component has received FDA approval for any indication as of September 2025: GLP3 in phase 3 development for obesity and type 2 diabetes (TRIUMPH trials ongoing) Cagrilintide in phase 3 development as part of CagriSema combination Combined GLP3 + cagrilintide formulation not under regulatory review Not legally available for medical use, compounding, or human consumption No established therapeutic use basis for the combination Both peptides remain investigational drugs under active clinical development by their respective manufacturers
US$ 26.34
US$ 25.59
US$ 29.60
US$ 28.23
US$ 22.82
US$ 27.28
US$ 21.25
US$ 28.59
US$ 25.44
US$ 20.91
